GLUE - Monte Rosa Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

GLUE is currently covered by 4 analysts with an average price target of $11.49. This is a potential upside of $4.56 (65.8%) from yesterday's end of day stock price of $6.93.

Monte Rosa Therapeutics's activity chart (see below) currently has 6 price targets and 16 ratings on display. The stock rating distribution of GLUE is 40% HOLD and 60% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 38.33% with an average time for these price targets to be met of 55.4 days.

Highest price target for GLUE is $16, Lowest price target is $11, average price target is $11.49.

Most recent stock forecast was given by DEREK ARCHILA from WELLS FARGO on 19-Dec-2024. First documented stock forecast 19-Jul-2021.

Best performing analysts who are covering GLUE - Monte Rosa Therapeutics:

Eric Joseph Andrew Berens Derek Archila Edward Tenthoff Richard Law

Currently out of the existing stock ratings of GLUE, 4 are a HOLD (40%), 6 are a BUY (60%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$11

$4.07 (58.73%)

$17

2 days ago
(19-Dec-2024)

0/4 (0%)

$4.43 (67.43%)

Buy

$16

$9.07 (130.88%)

$21

5 months 23 days ago
(28-Jun-2024)

1/4 (25%)

$12.26 (327.81%)

45

Buy

$10

$3.07 (44.30%)

$11

1 years 1 months 12 days ago
(09-Nov-2023)

2/3 (66.67%)

$6.7 (203.03%)

203

Hold

$11

$4.07 (58.73%)

$11

1 years 4 months 10 days ago
(11-Aug-2023)

0/4 (0%)

$4.31 (64.42%)

Hold

$20

$10.81 (117.63%)

3 years 2 months ago
(21-Oct-2021)

1/1 (100%)

$-4.92 (-19.74%)

29

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is GLUE (Monte Rosa Therapeutics) average time for price targets to be met?

On average it took 55.4 days on average for the stock forecasts to be realized with a an average price target met ratio 38.33

Which analyst has the current highest performing score on GLUE (Monte Rosa Therapeutics) with a proven track record?

ERIC JOSEPH

Which analyst has the current lower performing score on GLUE (Monte Rosa Therapeutics) with a proven track record?

RICHARD LAW

Which analyst has the most public recommendations on GLUE (Monte Rosa Therapeutics)?

Eric Joseph works at JPMORGAN and has 10 price targets and 5 ratings on GLUE

Which analyst is the currently most bullish on GLUE (Monte Rosa Therapeutics)?

Andrew Berens with highest potential upside - $10.81

Which analyst is the currently most reserved on GLUE (Monte Rosa Therapeutics)?

Eric Joseph with lowest potential downside - $3.07

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?